402 related articles for article (PubMed ID: 15141010)
1. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
2. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
3. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Krystal GW; Sulanke G; Litz J
Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
8. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Maulik G; Bharti A; Khan E; Broderick RJ; Kijima T; Salgia R
J Environ Pathol Toxicol Oncol; 2004; 23(4):237-51. PubMed ID: 15511212
[TBL] [Abstract][Full Text] [Related]
9. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
10. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Litz J; Krystal GW
Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
Zhou H; Rao J; Lin J; Yin B; Sheng H; Lin F; Zhang N; Yang L
Oncol Rep; 2011 Jun; 25(6):1565-71. PubMed ID: 21455580
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
13. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
14. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
16. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Bondzi C; Litz J; Dent P; Krystal GW
Cell Growth Differ; 2000 Jun; 11(6):305-14. PubMed ID: 10910097
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
18. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
19. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal GW; Hines SJ; Organ CP
Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
